Pathos AI secures $55M Tempus deal, BMS leads Series E

Bristol Myers Squibb (BMY) presented interim Phase 1 study results for zolacabtagene autoleucel, a CAR T cell therapy for multiple sclerosis, at the MSToronto 2026 meeting. The study enrolled 66 patients, with safety and efficacy as primary and secondary endpoints. Key findings included cytokine release syndrome in 42.4% of patients, one death from septic pneumonia, and positive efficacy signals in both relapsing and progressive MS patients.

Tempus AI and Bristol Myers Squibb extended their partnership with a multi-year deal for oncological data and AI platform access. The agreement, running through 2031, includes $137.5 million from Bristol Myers and $55 million from Pathos AI for patient records. Pathos AI is also collaborating with both companies on neurological conditions.

Bristol Myers Squibb (BMY) presented interim Phase 1 Breakfree-2 study results for zolacabtagene autoleucel (zola-cel) in patients with highly active relapsing and progressive multiple sclerosis (MS). The study showed promising safety and efficacy, with 42.4% of patients experiencing cytokine release syndrome (CRS) and 7.6% immune effector cell-associated neurotoxicity syndrome (ICANS). All patients treated at dose level 2 remained off disease-modifying therapies (DMTs).

Bristol Myers Squibb (BMY) shared interim Phase 1 data for zola-cel in multiple sclerosis, showing safety consistent with prior trials and all 60 patients off disease-modifying therapies. One Grade 5 septic pneumonia case was reported in haRMS.

Tempus AI (TEM) and Bristol Myers Squibb (BMY) extended their collaboration with a multi-year agreement. BMY will license Tempus' oncology data through 2031 and access its AI-driven Lens Platform for drug discovery. The deal expands their existing partnership in AI and data-driven oncology research.

Pathos AI has partnered with Bristol Myers Squibb (BMY) and Tempus (TEM) for a multi-year collaboration to develop AI-driven datasets and capabilities for Alzheimer's and neurological conditions. BMY leads Pathos's Series E financing and gains access to Pathos Foundry. Tempus will provide a de-identified dataset for $55 million over five years. Pathos will use its AI platform to analyze the data and design clinical trials.